Arcus Biosciences (RCUS) Current Assets (2017 - 2026)

Arcus Biosciences' Current Assets history runs 10 years deep, the most recent figure standing at $844.0 million for Q1 2026.

• In Q1 2026, Current Assets fell 18.14% year-over-year to $844.0 million; the TTM figure through Mar 2026 stood at $844.0 million (down 18.14% YoY), while the FY2025 annual figure was $1.0 billion, down 0.89% from the prior year.
• Current Assets was $844.0 million for Q1 2026 at Arcus Biosciences, down from $1.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.3 billion in Q1 2022 to a low of $831.0 million in Q4 2023.
• Historically, Current Assets has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 101.93% in 2022, then fell 23.96% in 2025.
• A 5-year view of Current Assets shows it stood at $1.1 billion in 2022, then decreased by 22.12% to $831.0 million in 2023, then grew by 22.26% to $1.0 billion in 2024, then retreated by 0.89% to $1.0 billion in 2025, then declined by 16.19% to $844.0 million in 2026.
• The last three Current Assets figures came in at $844.0 million (Q1 2026), $1.0 billion (Q4 2025), and $857.0 million (Q3 2025), per Business Quant data.